

## ASX Announcement

### Regeneus joins Austrade's business mission in Japan

Sydney, Australia - 18 April 2017

Regeneus Ltd (ASX: RGS), a clinical-stage regenerative medicine company, today announced that John Martin, CEO, will be participating in Austrade's business delegation to Japan on April 18 and 19 being led by the Hon Steven Ciobo MP, Minister for Trade, Tourism and Investments.

Organised by Austrade, the Australian government's export, international education and foreign investment promotion agency, this two-day mission will showcase leading Australian capabilities in a range of key sectors including regenerative medicine which is an area of particular interest in Japan. The Japanese market offers significant growth opportunities for Australian regenerative medicine companies and Japanese businesses are looking to Australia for solutions in response to the implementation of the Japan Australia Economic Partnership Agreement.

The Mission will include a roundtable session with the Forum for Innovative Regenerative Medicine (FIRM) and Japan BioIndustry Association (JBA) executives. In 2015, FIRM and Austrade signed an MoU to jointly enhance collaboration between Australia and Japan in the regenerative medicine sector. There have already been a number of activities between Australia and Japan including business missions and roundtables. This round table aims to build on this momentum.

There will be a reception to commemorate the 60<sup>th</sup> Anniversary of the Australia-Japan Commerce treaty with Mr Ciobo and Australia's Foreign Minister, Ms Julie Bishop.

The Mission will be attended by over 60 Japanese pharmaceutical and healthcare companies, where Mr Martin will be presenting Regeneus' portfolio of clinical-stage regenerative medicine therapies and proprietary technology platforms.

Regeneus has targeted Japan as a key market for licensing of its regenerative medicine products and was pleased to announce on 29 December 2016 a collaboration with AGC, a leading Japanese biopharmaceutical manufacturer, for the manufacture and development of its Progenza allogeneic stem cell therapy technology platform for the Japanese market. Regeneus is advanced in its discussions with Japanese pharmaceutical and healthcare companies interested in licensing Progenza technology for a range of clinical applications.

The market in Japan for regenerative medicines is projected to grow to US\$12.7bn by 2030 according to the Japanese government. The development of the regenerative medicine industry is one of the pillars of the growth strategy of the Abe Administration. In November 2014, Japan introduced new laws to enhance the development of the regenerative market including a significantly shorter approval process for commercialisation for new regenerative medicine therapies.

ENDS

**About Regeneus**

Regeneus Ltd (ASX: RGS) is an Australian-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and all other inflammatory conditions, oncology and skin disorders.

**Contact for further information:****Investor Relations**

Sandra McIntosh

Regeneus Ltd

T: +61 2 9499 8010

M: +450 253059

E: [investors@regeneus.com.au](mailto:investors@regeneus.com.au)

[www.regeneus.com.au](http://www.regeneus.com.au)